Semax reduced amyloid plaques in Alzheimer's model mice
In mice used as an Alzheimer's model, one month of nasal Semax reduced amyloid plaques in the cortex by 2.8 times and improved cognitive tests. The results are preliminary and show no direct effect in people.
Added on today
Source: Semax Reduced Amyloid Plaques in Alzheimer’s Model Mice (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
A report describes experiments with Alzheimer's model mice, animals used to study the disease. According to the publication, one month of nasal Semax reduced amyloid plaques, deposits associated with Alzheimer's, in the cortex of these animals by 2.8 times. The mice also performed better on cognitive tests, and the reduction in plaques persisted for 1.5 months after treatment was stopped.
Semax is a peptide developed in Russia and is not approved as an Alzheimer's treatment in countries such as the United States or those in Europe. Results in mice often do not carry over to people, because the brain, the disease and the way a substance is given can differ. This finding does not show whether the substance works in humans or whether it is safe for them.
What it means
The finding suggests that, in animals, Semax may reduce a marker associated with Alzheimer's and improve performance on memory and cognition tests. It is still unknown whether this happens in people, how safe it would be, or how long any effect would last. This is a preliminary result obtained in animals.
How to read it with care
A result in mice does not replace a medical consultation. Anyone considering any change in diet, supplements or treatment should talk to a doctor or another qualified professional.